RCS - Advanced Oncotherapy - LIGHT system potential in delivering FLASH

Advanced OncotherapyAnnouncement

11/05/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220511:nRSK0219La&default-theme=true

RNS Number : 0219L  Advanced Oncotherapy PLC  11 May 2022

Reach non-regulatory announcement

 

11 May 2022

 

ADVANCED ONCOTHERAPY PLC

 

("Advanced Oncotherapy" or the "Company")

 

Scientific publications highlight potential of LIGHT system in effectively
delivering FLASH radiotherapy

 

Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the next-generation
proton therapy system for cancer treatment, notes the recent publication of
two papers showcasing the potential superiority of the LIGHT system, over
other existing proton therapy systems, in the delivery of FLASH.

 

In the first paper titled "Ultra-high dose rate radiation production and
delivery systems intended for FLASH"(1) written by Jonathan Farr, Chief
Clinical Officer at the Company, and his co-authors, the LIGHT system was
assessed and it has been shown that it is ideally positioned to deliver FLASH,
as it is a 'pulsed system' sending out up to 500 million protons in each
burst, at 200 times per second. The number of particles per pulse has been
noted as a critical FLASH parameter for other (electron) systems, and now it
is becoming available from LIGHT for proton FLASH treatments.

 

In the second paper titled "Treatment planning for FLASH radiotherapy: General
aspects and applications to proton beams"(2), Anna Kolano, a Medical Physicist
at the Company, and her co-authors highlight the applicability of FLASH in
patient treatment. FLASH proton therapy is currently administered clinically
with "Shoot-Through FLASH Beams", analogous to X-rays, as legacy proton
systems require thick physical beam absorbers to achieve the lower energies
required for patient treatment. However, the LIGHT system, which produces all
energies electronically, is designed to deliver FLASH treatments anywhere in
the human body. Hence, the LIGHT FLASH plan for "Conformal Scanned FLASH
Beams" is conceptually superior to the Shoot-Through method.

 

Dr Jonathan Farr, Chief Clinical Officer at Advanced Oncotherapy said:

 

"The results published showcase the potential superiority of the LIGHT system
for delivering FLASH radiotherapy. FLASH proton therapy provides the potential
to change clinical practice and improve patient outcomes, as it could see
patients treated in a single session with significantly reduced normal tissue
toxicity burden post-treatment, and the Company's LIGHT system is ideally
positioned to deliver it. There is an urgent need to treat more cancer
patients while reducing the toxicity burden, which can damage healthy tissue,
associated with legacy radiation therapy systems."

 

Notes

1- Farr, J, Grilj, V, Malka, V, Sudharsan, S, Schippers, M. Ultra-High dose
rate radiation production and delivery systems intended for FLASH. Med Phys
2022; 00 1- 37. https://doi.org/10.1002/mp.15659
(https://doi.org/10.1002/mp.15659)

2- Schwarz, M, Traneus, E, Safai, S, Kolano, A, van de Water, S. Treatment
planning for FLASH radiotherapy: General aspects and applications to proton
beams. Med Phys. 2022; 49: 2861- 2874. https://doi.org/10.1002/mp.15579
(https://doi.org/10.1002/mp.15579)

 

- ENDS -

 

 

 Advanced Oncotherapy plc                                  www.avoplc.com (http://www.avoplc.com)
 Dr. Michael Sinclair, Executive Chairman                  Tel: +44 (0) 20 3617 8728
 Nicolas Serandour, CEO

 Allenby Capital Limited (Nomad and Joint Broker)
 Nick Athanas / Liz Kirchner (Corporate Finance)           Tel: +44 (0) 20 3328 5656

 Amrit Nahal / Matt Butlin (Sales and Corporate Broking)

 SI Capital Ltd (Joint Broker)
 Nick Emerson                                              Tel: +44 (0) 1483 413 500
 Jon Levinson                                              Tel: +44 (0) 20 3871 4066

 FTI Consulting (Financial PR & IR)                        advancedoncotherapy@fticonsulting.com
                                                           (mailto:advancedoncotherapy@fticonsulting.com)
 Simon Conway / Rob Winder                                 Tel: +44 (0) 20 3727 1000

 

About FLASH radiotherapy

FLASH radiotherapy, in which ultra-high radiation doses, several orders of
magnitude higher than that currently used in conventional clinical
radiotherapy, are delivered in fractions of a second, offers the potential to
treat cancer patients in a single visit, rather than up to 30 visits with
conventional radiation therapy, and has the potential to revolutionise the
future of cancer treatment.

 

About Advanced Oncotherapy Plc

 

Advanced Oncotherapy, a UK headquartered company with offices in London,
Geneva, The Netherlands and in the USA, is a provider of particle therapy with
protons that harnesses the best in modern technology. Advanced Oncotherapy's
team "ADAM," based in Geneva, focuses on the development of a proprietary
proton accelerator called, Linac Image Guided Hadron Technology (LIGHT).
LIGHT's compact configuration delivers proton beams in a way that facilitates
greater precision and electronic control.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that
will enable them to treat cancer with innovative technology as well as
expected lower treatment-related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging
improvements in delivering proton therapy and actively seeks working
relationships with providers of these innovative technologies. Through these
relationships, the Company will remain the prime provider of an innovative and
cost-effective system for particle therapy with protons.

 

About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service aimed
at assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases into the public domain.
Information required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an RNS
regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABKKBKDBKBQPD